Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vascular Endothelial Growth Factor (VEGF) is a family of secreted glycoproteins that regulate vasculogenesis, angiogenesis, and lymphangiogenesis. VEGF-A is the most studied isoform. VEGFs function as homodimers and bind to tyrosine kinase receptors (VEGFR-1, VEGFR-2, VEGFR-3) to induce endothelial cell proliferation, migration, and survival, increasing vascular permeability. Dysregulation of the VEGF pathway is implicated in tumor growth and ocular diseases. Anti-VEGF therapies target the ligand or its receptors to inhibit abnormal vessel growth or reduce vascular leakage. Serum concentrations can be elevated in conditions such as bronchial asthma or diabetes mellitus.
Inhibition of VEGF binding to VEGFRs, thereby blocking downstream signaling cascades involved in angiogenesis, cell survival, proliferation, and migration.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vascular Endothelial Growth Factor (VEGF).